[{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Podiatry","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BAY1193397","moa":"Adrenergic receptor alpha-2C (ADRA2C)","graph1":"Podiatry","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Private Placement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane||Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lakewood-Amedex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Undisclosed"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane||Cell membrane structures","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lakewood-Amedex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Undisclosed"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Professional Education and Research Institute | PrimeVigilance Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lakewood-Amedex \/ Professional Education and Research Institute | PrimeVigilance Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Professional Education and Research Institute | PrimeVigilance Ltd"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lakewood-Amedex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Undisclosed"},{"orgOrder":0,"company":"Bridge BioResearch","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Podiatry","graph2":"Phase II","graph3":"Bridge BioResearch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bridge BioResearch \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge BioResearch \/ Undisclosed"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Podiatry","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Skingenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Sesame Oil","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Skingenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Skingenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skingenix \/ Undisclosed"},{"orgOrder":0,"company":"Skingenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Sesame Oil","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Skingenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Skingenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skingenix \/ Undisclosed"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AUP1602-C","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Aurealis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurealis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AUP1602-C","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Aurealis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurealis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Srinakharinwirot University","sponsor":"Oxo Chemie | Altermed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"THAILAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"WF10","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Srinakharinwirot University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Srinakharinwirot University \/ Oxo Chemie | Altermed","highestDevelopmentStatusID":"8","companyTruncated":"Srinakharinwirot University \/ Oxo Chemie | Altermed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Podiatry","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tapentadol","moa":"Mu opioid receptor | Norepinephrine transporter","graph1":"Podiatry","graph2":"Phase II","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Grunenthal \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grunenthal \/ Undisclosed"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Podiatry","graph2":"Phase II","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PluroGen Therapeutics","sponsor":"Arkios BioDevelopment International","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Plurogel N","moa":"Skin barrier","graph1":"Podiatry","graph2":"Phase II","graph3":"PluroGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"PluroGen Therapeutics \/ Arkios BioDevelopment International","highestDevelopmentStatusID":"8","companyTruncated":"PluroGen Therapeutics \/ Arkios BioDevelopment International"},{"orgOrder":0,"company":"PluroGen Therapeutics","sponsor":"Arkios BioDevelopment International","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Plurogel Pn","moa":"Skin barrier","graph1":"Podiatry","graph2":"Phase II","graph3":"PluroGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"PluroGen Therapeutics \/ Arkios BioDevelopment International","highestDevelopmentStatusID":"8","companyTruncated":"PluroGen Therapeutics \/ Arkios BioDevelopment International"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"local anesthetics||Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Catherine Vandepitte","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase II","graph3":"Catherine Vandepitte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catherine Vandepitte \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Catherine Vandepitte \/ Pacira BioSciences"},{"orgOrder":0,"company":"Charsire Biotechnology","sponsor":"ASKLEP Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CSTC1","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Charsire Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charsire Biotechnology \/ ASKLEP Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Charsire Biotechnology \/ ASKLEP Inc."},{"orgOrder":0,"company":"Jiangsu ProteLight Pharmaceutical & Biotechnology","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Antimicrobial Peptide PL-5","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Jiangsu ProteLight Pharmaceutical & Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jiangsu ProteLight Pharmaceutical & Biotechnology \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu ProteLight Pharmaceutical & Biotechnology \/ Parexel"},{"orgOrder":0,"company":"Blue Blood Biotech Corp.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BB-101","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Blue Blood Biotech Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Blood Biotech Corp. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blue Blood Biotech Corp. \/ Undisclosed"},{"orgOrder":0,"company":"Blue Blood Biotech Corp.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BB-101","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Blue Blood Biotech Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Blood Biotech Corp. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blue Blood Biotech Corp. \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Diamel","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Joseph Boykin, MD","sponsor":"George Mason University | Central Arkansas Veterans Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Folinic Acid Calcium Salt","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Joseph Boykin, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Boykin, MD \/ George Mason University | Central Arkansas Veterans Healthcare System","highestDevelopmentStatusID":"8","companyTruncated":"Joseph Boykin, MD \/ George Mason University | Central Arkansas Veterans Healthcare System"},{"orgOrder":0,"company":"Izun Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IZN-6D4","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Izun Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Izun Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Izun Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"OcuNexus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"Lufepirsen","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"OcuNexus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OcuNexus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuNexus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MDI-1228","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NGI226","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Pep Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Rion \/ Professional Education and Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"Microbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ US Navy"},{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0.02,"dosageForm":"Suspension","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CARB-X"},{"orgOrder":0,"company":"Microbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"CUBRC | National Medical Research Council, Singapore | MTEC","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbion \/ CUBRC | National Medical Research Council, Singapore | MTEC","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CUBRC | National Medical Research Council, Singapore | MTEC"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Undisclosed"},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Discovery Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Discovery Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Discovery Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lynch Biologics","sponsor":"Medelis | Centro M\u00e9dico Militar","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Lynch Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lynch Biologics \/ Medelis | Centro M\u00e9dico Militar","highestDevelopmentStatusID":"8","companyTruncated":"Lynch Biologics \/ Medelis | Centro M\u00e9dico Militar"},{"orgOrder":0,"company":"Centrexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Podiatry","graph2":"Phase II","graph3":"Centrexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centrexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centrexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Centrexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Podiatry","graph2":"Phase II","graph3":"Centrexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centrexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centrexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target